Managing Anxiety During Pregnancy: A Guide to Medications, Risks, and Informed Decisions

For women living with anxiety disorders, the prospect of pregnancy raises a set of questions that are deeply personal and medically nuanced. Should I continue my medication? What are the risks to my baby? What happens if I stop? These are not questions with simple universal answers—but they are questions that deserve thoughtful, evidence-based responses rather than reflexive fear or dismissal.

The reality that many patients do not hear loudly enough is this: untreated anxiety during pregnancy carries its own documented risks. Framing the decision as "medication versus safety" misrepresents the actual choice, which is more accurately described as weighing one set of risks against another.

Why This Conversation Is Harder Than It Should Be

Anxiety disorders affect approximately 20 percent of pregnant women in the United States, making them among the most common mental health conditions during the perinatal period. Yet many women discontinue their medications without medical guidance the moment they see a positive pregnancy test, often out of fear and without a clear plan.

This pattern is understandable. Messaging around substances during pregnancy tends to be absolutist, and the nuance required to discuss psychiatric medication safety can feel inaccessible. Healthcare providers, for their part, sometimes lack the time or specialized training to address these questions thoroughly during a standard obstetric appointment.

The result is a gap between what women need to know and what they are actually told—a gap that Attarax Relief aims to help address by presenting the current state of evidence clearly and without sensationalism.

The Real Risks of Untreated Anxiety in Pregnancy

Moderate to severe anxiety during pregnancy is not a benign backdrop to an otherwise healthy gestation. Research has linked untreated anxiety disorders to:

• Elevated cortisol levels that may affect fetal neurodevelopment
• Increased risk of preterm labor and low birth weight
• Higher rates of preeclampsia in some studies
• Postpartum depression and anxiety, which can affect mother-infant bonding
• Behavioral and developmental differences in children observed in some longitudinal studies

These associations do not mean that anxiety disorders doom a pregnancy—many women with anxiety have entirely healthy pregnancies and children. But they do underscore that the decision to discontinue medication is not automatically the "safer" choice.

Reviewing the Medication Categories

SSRIs and SNRIs

Selective serotonin reuptake inhibitors (SSRIs) are the most studied class of psychiatric medications in pregnancy and are generally considered the first-line pharmacological option for anxiety disorders in pregnant women who require treatment. Sertraline (Zoloft) and escitalopram (Lexapro) are among the most commonly used, with sertraline having the most extensive safety data.

The available evidence suggests that the absolute risk of major birth defects from SSRI use is low. However, there are some associations worth discussing with your provider:

• A modestly elevated risk of cardiac septal defects has been reported with paroxetine (Paxil) specifically, which is why it is generally avoided during pregnancy
• Persistent pulmonary hypertension of the newborn (PPHN) has been associated with late-pregnancy SSRI use in some studies, though the absolute risk remains small
• Neonatal adaptation syndrome—a transient condition involving jitteriness, feeding difficulties, and mild respiratory symptoms in newborns—can occur when SSRIs are used close to delivery

SNRIs such as venlafaxine and duloxetine have less data than the most-studied SSRIs but are not generally considered high-risk based on current evidence.

Benzodiazepines

Benzodiazepines present a more complicated picture. Earlier studies suggested links to cleft palate and other structural defects, but more recent, better-controlled research has substantially weakened those associations. The current consensus is that the teratogenic risk of benzodiazepines, while not zero, is likely lower than once feared.

The more significant concerns with benzodiazepine use during pregnancy are:

• Neonatal withdrawal syndrome, which can occur when the drug is used regularly in the third trimester
• Floppy infant syndrome, characterized by hypotonia and respiratory depression in newborns exposed close to delivery
• Long-term dependence risks for the mother, which may complicate the postpartum period

Benzodiazepines may be used judiciously for acute anxiety management during pregnancy, but sustained daily use carries risks that most providers will want to minimize.

Buspirone

Buspirone, a non-benzodiazepine anxiolytic, has limited human pregnancy data. Animal studies have not shown teratogenic effects, but the absence of robust human evidence means most providers exercise caution and reserve it as an option only when the benefit-risk calculation clearly favors use.

Hydroxyzine

Hydroxyzine, an antihistamine with anxiolytic properties, is sometimes used for situational anxiety. It is generally avoided in the first trimester due to some early studies suggesting a possible association with birth defects, and it is not recommended close to delivery due to potential neonatal effects. It may have a role in limited, carefully considered circumstances during mid-pregnancy.

Breastfeeding Considerations

The postpartum period brings its own anxieties, and many women wish to breastfeed while managing their mental health. The good news is that several medications have reassuring breastfeeding profiles:

• Sertraline and paroxetine transfer into breast milk at very low levels and are generally considered compatible with breastfeeding
• Nortriptyline and imipramine (older tricyclics) also have low transfer rates
• Fluoxetine tends to accumulate more in breast milk and is generally not preferred for new breastfeeding mothers, though it is not absolutely contraindicated

Benzodiazepines are typically used with caution during breastfeeding due to potential sedation effects in the infant.

The LactMed database, maintained by the National Institutes of Health, is a freely accessible resource that provides detailed, regularly updated information on medication transfer into breast milk.

Timing and Planning: Before Conception

For women who are planning a pregnancy rather than responding to an unexpected one, there is an important window of opportunity for proactive planning. Ideally, discussions about medication management should begin well before conception, allowing time to:

• Stabilize on a medication with a more favorable pregnancy profile if a switch is warranted
• Explore whether psychotherapy alone (particularly CBT) might provide sufficient control to allow for medication tapering
• Establish care with a maternal-fetal medicine specialist or a reproductive psychiatrist if the case is complex

Rushing into medication changes during the first trimester—the most critical period of fetal organ development—is precisely what advance planning is designed to avoid.

Having the Conversation With Your Provider

If your current provider seems reluctant to engage with this topic in depth, it is entirely reasonable to request a referral to a reproductive psychiatrist or a perinatal mental health specialist. These clinicians have specific expertise in managing psychiatric conditions during the perinatal period and can provide nuanced guidance that a general practitioner or even a general psychiatrist may not be equipped to offer.

Come to appointments prepared with specific questions: Which of my current medications has the most favorable pregnancy data? What are the risks if I stay on it versus tapering off? What symptoms should prompt me to call you immediately?

Moving Forward With Clarity

There is no universally correct answer to the question of anxiety medication during pregnancy. What exists is a growing body of evidence, a range of clinical tools, and the possibility of a genuinely informed decision made in partnership with qualified providers.

The goal is not a risk-free pregnancy—no such thing exists—but a thoughtfully managed one, in which both the mother's mental health and the developing baby's wellbeing are treated as equally legitimate priorities.